BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28779511)

  • 21. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
    Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
    Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
    Minami SS; Clifford TG; Hoe HS; Matsuoka Y; Rebeck GW
    Neurobiol Aging; 2012 Apr; 33(4):825.e15-24. PubMed ID: 21741124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
    Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
    Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer's disease models.
    Song JX; Malampati S; Zeng Y; Durairajan SSK; Yang CB; Tong BC; Iyaswamy A; Shang WB; Sreenivasmurthy SG; Zhu Z; Cheung KH; Lu JH; Tang C; Xu N; Li M
    Aging Cell; 2020 Feb; 19(2):e13069. PubMed ID: 31858697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selenomethionine Mitigates Cognitive Decline by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model.
    Zhang ZH; Wu QY; Zheng R; Chen C; Chen Y; Liu Q; Hoffmann PR; Ni JZ; Song GL
    J Neurosci; 2017 Mar; 37(9):2449-2462. PubMed ID: 28137967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model.
    Martínez-Mármol R; Mohannak N; Qian L; Wang T; Gormal RS; Ruitenberg MJ; Vanhaesebroeck B; Coulson EJ; Meunier FA
    J Neurosci; 2019 Oct; 39(40):7976-7991. PubMed ID: 31363064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice.
    España J; Giménez-Llort L; Valero J; Miñano A; Rábano A; Rodriguez-Alvarez J; LaFerla FM; Saura CA
    Biol Psychiatry; 2010 Mar; 67(6):513-21. PubMed ID: 19664757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 9R, the cholinesterase and amyloid beta aggregation dual inhibitor, as a multifunctional agent to improve cognitive deficit and neuropathology in the triple-transgenic Alzheimer's disease mouse model.
    Ju Y; Tam KY
    Neuropharmacology; 2020 Dec; 181():108354. PubMed ID: 33035533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flavanol-rich lychee fruit extract substantially reduces progressive cognitive and molecular deficits in a triple-transgenic animal model of Alzheimer disease.
    Chen X; Xu B; Nie L; He K; Zhou L; Huang X; Spencer P; Yang X; Liu J
    Nutr Neurosci; 2021 Sep; 24(9):720-734. PubMed ID: 31603034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transgenic autoinhibition of p21-activated kinase exacerbates synaptic impairments and fronto-dependent behavioral deficits in an animal model of Alzheimer's disease.
    Bories C; Arsenault D; Lemire M; Tremblay C; De Koninck Y; Calon F
    Aging (Albany NY); 2017 May; 9(5):1386-1403. PubMed ID: 28522792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background.
    Virgili J; Lebbadi M; Tremblay C; St-Amour I; Pierrisnard C; Faucher-Genest A; Emond V; Julien C; Calon F
    Synapse; 2018 Apr; 72(4):. PubMed ID: 29341269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
    Guo Q; Li H; Cole AL; Hur JY; Li Y; Zheng H
    PLoS One; 2013; 8(11):e80706. PubMed ID: 24278307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer's disease.
    Hong Y; Chan CB; Kwon IS; Li X; Song M; Lee HP; Liu X; Sompol P; Jin P; Lee HG; Yu SP; Ye K
    J Neurosci; 2012 Nov; 32(48):17262-72. PubMed ID: 23197718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. APP/Go protein Gβγ-complex signaling mediates Aβ degeneration and cognitive impairment in Alzheimer's disease models.
    Bignante EA; Ponce NE; Heredia F; Musso J; Krawczyk MC; Millán J; Pigino GF; Inestrosa NC; Boccia MM; Lorenzo A
    Neurobiol Aging; 2018 Apr; 64():44-57. PubMed ID: 29331876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
    Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
    J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease.
    Martínez-Drudis L; Sheta R; Pellegrinato R; Loukili S; Tremblay C; Calon F; Rivest S; Oueslati A
    Neurobiol Dis; 2022 Oct; 172():105833. PubMed ID: 35905928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.